Metastasis-directed therapy (MDT) significantly improved outcomes in patients with oligometastatic prostate cancer, according to a new study from researchers at The University of Texas MD Anderson Cancer Center published in The Lancet Oncology. The study is a first-of-its-kind meta-analysis of individual patients across all available randomized clinical trials evaluating the addition of metastasis-directed radiation therapy to standard-of-care treatment.